Abbott and AstraZeneca announced today that they were discontinuing their collaboration for the development of Certriad, the combination of rosuvastatin and fenofibric acid. The companies received a Complete Response Letter from the FDA earlier this year, and said “the resulting regulatory delay and the commercial attractiveness of the product in the U.S. market.”
Abbott and AstraZeneca End License Agreement for the Development of CERTRIAD™
December 22, 2010
Abbott Park, Illinois PARK, Ill., Dec. 22, 2010 –Abbott announced today that Abbott and AstraZeneca will discontinue their joint collaboration for the development of CERTRIAD™ (rosuvastatin / fenofibric acid delayed release) Capsules. The companies reached this decision after careful consideration of the Complete Response Letter received from the U.S. Food and Drug Administration, the resulting regulatory delay and the commercial attractiveness of the product in the U.S. market.
There will be no financial impact to Abbott’s ongoing earnings per share in 2010 or 2011 resulting from this action.
About Abbott
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs nearly 90,000 people and markets its products in more than 130 countries.
Speak Your Mind